Interestingly, subset analysis of ovarian cancer patients treated with gefitinib suggests the likelihood of response to be related to the presence of a mutation in the catalytic domain of EGFR as previously described in lung cancer. The gene discussed is EGFR; the disease is ovarian carcinoma.